Disease-specific cost savings of treating nighttime versus daytime gastroesophageal reflux disease in an employed population.

Autor:	Doan QV; Cerner LifeSciences, Beverly Hills, CA, USA. qdoan@cerner.com, Lange SM, Elfant A, Aguilar D, Reyes E, Lynn RB, Dubois RW
Jazyk:	angličtina
Zdroj:	Journal of medical economics [J Med Econ] 2008; Vol. 11 (1), pp. 23-40.
DOI:	10.3111/13696990701815545
Abstrakt:	Objective: The extent to which proton pump inhibitors (PPIs) can offset direct medical costs by reducing symptoms related to gastroesophageal reflux disease (GERD) in order to improve work productivity is not well understood. This study aimed to evaluate the economic impact of treating GERD with PPIs versus no treatment, from an employer's perspective. Study Design: An economic model was developed to simulate symptom reduction and breakthrough symptoms as well as associated costs over 1 year among a population of 100,000 with a 20% GERD prevalence rate. Medical costs, including GERD-related office visits, hospitalisations and procedures, were delineated by symptom severity. Indirect costs represented the monetised work productivity loss. PPI treatment costs $2/day (standard dose). Results: The GERD burden was substantial ($62,500,000). Treatment yielded $32,600,000 in savings ($1,630 saved/patient/year), mostly from reducing indirect costs. Treatment produced greater savings among nighttime GERD patients throughout the PPI cost range ($1-$5/day). Savings dropped if the price of standard doses of PPI exceeded $3.92/day for the treatment of daytime GERD patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu